Schwartz D H
Dept of Immunology and Infectious Diseases, Johns Hopkins University School of Hygiene and PUblic Health, Baltimore, MD 21205.
Immunol Today. 1994 Feb;15(2):54-7. doi: 10.1016/0167-5699(94)90133-3.
Experimental vaccines for AIDS prophylaxis are being tested in larger and higher-risk populations. Here, David Schwartz, an advocate of HIV-vaccine research and development, highlights some of the concerns that have been voiced about this strategy and presents a simple mathematical model that considers the drawbacks to vaccine-induced expansion of HIV-specific CD4+ T cells.
用于预防艾滋病的实验性疫苗正在更大规模、风险更高的人群中进行测试。在此，艾滋病疫苗研发倡导者大卫·施瓦茨强调了针对该策略提出的一些担忧，并提出了一个简单的数学模型，该模型考虑了疫苗诱导的HIV特异性CD4+ T细胞扩增的弊端。
